Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yvette Zou"'
Autor:
Samuel B. Brusca, Jason M. Elinoff, Yvette Zou, Moon Kyoo Jang, Hyesik Kong, Cumhur Y. Demirkale, Junfeng Sun, Fayaz Seifuddin, Mehdi Pirooznia, Hannah A. Valantine, Carl Tanba, Abhishek Chaturvedi, Grace M. Graninger, Bonnie Harper, Li-Yuan Chen, Justine Cole, Manreet Kanwar, Raymond L. Benza, Ioana R. Preston, Sean Agbor-Enoh, Michael A. Solomon
Publikováno v:
Circulation. 146(14)
Background: Cell-free DNA (cfDNA) is a noninvasive marker of cellular injury. Its significance in pulmonary arterial hypertension (PAH) is unknown. Methods: Plasma cfDNA was measured in 2 PAH cohorts (A, n=48; B, n=161) and controls (n=48). Data were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bddf055d914a456677cd9a6775538e7
https://pubmed.ncbi.nlm.nih.gov/36004627
https://pubmed.ncbi.nlm.nih.gov/36004627
Autor:
Mengyun Lu, Li-Yuan Chen, Salina Gairhe, Adrien J. Mazer, Stasia A. Anderson, Jasmine N.H. Nelson, Audrey Noguchi, Mohammad Abdul Hai Siddique, Edward J. Dougherty, Yvette Zou, Kathryn A. Johnston, Zu-Xi Yu, Honghui Wang, Shuibang Wang, Junfeng Sun, Steven B. Solomon, Rebecca R. Vanderpool, Michael A. Solomon, Robert L. Danner, Jason M. Elinoff
Publikováno v:
Am J Physiol Lung Cell Mol Physiol
Treatment with mineralocorticoid receptor (MR) antagonists beginning at the outset of disease, or early thereafter, prevents pulmonary vascular remodeling in preclinical models of pulmonary arterial hypertension (PAH). However, the efficacy of MR blo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7fd447de0389ed9abf43b9ce0f191e8
https://europepmc.org/articles/PMC8858673/
https://europepmc.org/articles/PMC8858673/
Autor:
Samuel B Brusca, Jason M Elinoff, Yvette Zou, Moon K Jang, Hyesik Kong, Cumhur Y Demirkale, Junfeng Sun, Fayaz Seifuddin, Mehdi Pirooznia, Hannah A Valantine, Carl Tanba, Abhishek Chaturvedi, Manreet Kanwar, Raymond L Benza, Ioana R Preston, sean agborenoh, Michael A Solomon
Publikováno v:
Circulation. 144
Background: Cell-free DNA (cfDNA) is a non-invasive marker of tissue injury. Although being incrementally used as a clinical biomarker, its significance in pulmonary arterial hypertension (PAH) is unknown. Methods: Plasma cfDNA was isolated in two in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::232661ad4582520b739c4e08de28673c
https://doi.org/10.1161/circ.144.suppl_1.10765
https://doi.org/10.1161/circ.144.suppl_1.10765
Autor:
Yvette Zou, Junfeng Sun, Samuel B Brusca, H. Kong, Stasia A. Anderson, Zu-Xi Yu, Li-Yuan Chen, Audrey Noguchi, Jasmine Nelson, Sean Agbor-Enoh, Jason M. Elinoff, Michael A. Solomon, Moon Kyoo Jang
Publikováno v:
Circulation. 142
Introduction: Cell-free DNA (cfDNA) is released into circulation following tissue injury and cell turnover. In cancer and allograft rejection, cfDNA serves as a valuable biomarker for monitoring disease severity, progression, and response to therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3b109f339d6686f148f33d628f6d3e7
https://doi.org/10.1161/circ.142.suppl_3.15168
https://doi.org/10.1161/circ.142.suppl_3.15168
Publikováno v:
Curr Opin Pulm Med
Purpose of review The 6th World Symposium on Pulmonary Hypertension (WSPH) proposed lowering the mean pulmonary artery pressure (mPAP) threshold that defines pulmonary hypertension from ≥ 25 to > 20 mmHg. The historical context and evolution of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4e4776a3a3cae08f6b23e0eb3e7cccc
https://pubmed.ncbi.nlm.nih.gov/32701671
https://pubmed.ncbi.nlm.nih.gov/32701671